19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
00:01 , May 11, 2019 |  BC Innovations  |  Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
17:52 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest transferrin-conjugated liposomal nanoparticles loaded with temozolomide and an inhibitor of BET bromodomain proteins could help treat glioma. The liposomal nanoparticles contain distearoylglycerophosphoethanolamine (DSPE) conjugated to polyethylene glycol (PEG) and...
18:14 , Jun 1, 2018 |  BC Week In Review  |  Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
20:57 , May 30, 2018 |  BC Extra  |  Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013 deal to develop and commercialize up to four Probody drug conjugate candidates using...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
01:15 , Jan 12, 2018 |  BC Innovations  |  Product R&D

Avidity’s affinity for muscle

Avidity Biosciences LLC has developed a strategy for delivering siRNA and antisense therapies to tissues outside the liver and has preclinical proof-of-concept for two molecules that target muscle. The company has set its next sights...
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....